A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Proof-of-concept Study of Nicotinamide and Oral Tetrahydrouridine (THU) and Decitabine to Treat High Risk Sickle Cell Disease
Race/ethnicity-specific condition
Phase
PHASE1
Enrollment
20 (est.)
Age range
18 Years to —
Sex
ALL
Summary
A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
Conditions studied
Sickle Cell Disease
Sign-up window
Jan 24, 2020 – est. completion Oct 30, 2026
Sponsors
EpiDestiny, Inc.Lead
National Heart, Lung, and Blood Institute (NHLBI)Collaborator
National Institutes of Health (NIH)Collaborator
Study locations
University of Illinois at Chicago College of Medicine
Chicago, Illinois
Lani Krauz, CONTACT